<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01266759</url>
  </required_header>
  <id_info>
    <org_study_id>MU-261z</org_study_id>
    <secondary_id>FMH-245-C</secondary_id>
    <nct_id>NCT01266759</nct_id>
  </id_info>
  <brief_title>Efficacy of Combined Contraceptive Vaginal Ring(NuvaRing)in Women With Idiopathic Menorrhagia</brief_title>
  <official_title>Combined Contraceptive Vaginal Ring or Norethisterone for Treatment of Idiopathic Menorrhagia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mansoura University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mansoura University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare the efficacy of a combined contraceptive vaginal ring (NuvaRing) and oral
      Norethisterone Acetate in treatment of Idiopathic heavy menstrual bleeding during fertile age
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2008</start_date>
  <completion_date type="Actual">September 2010</completion_date>
  <primary_completion_date type="Actual">September 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction in menstrual blood loss at the end of study (cycle 3) measured by pictorial blood loss assessment chart.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Haemoglobin and serum ferritin at the end of study (cycle 3)</measure>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">95</enrollment>
  <condition>Menorrhagia</condition>
  <arm_group>
    <arm_group_label>NuvaRing</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>For the first cycle, women inserted the ring between days 1 and 5 of the menstrual cycle. Treatment continued for three cycles. Each cycle consisted of 3 weeks of ring use followed by a 1 week ring-free period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Norethisterone Acetate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Norethisterone Acetate tablets at a dose of 5 mg three times daily from day 5 to 26 of the cycle over three cycles. Male condom used for contraception during treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NuvaRing</intervention_name>
    <description>For the first cycle, women inserted the ring between days 1 and 5 of the menstrual cycle. Treatment continued for three cycles. Each cycle consisted of 3 weeks of ring use followed by a 1 week ring-free period.</description>
    <arm_group_label>NuvaRing</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Norethisterone Acetate tablets - 5mg</intervention_name>
    <description>Norethisterone Acetate tablets 5 mg three times daily from day 5 to 26 of the cycle over three cycles. Male condom used for contraception during treatment</description>
    <arm_group_label>Norethisterone Acetate</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women with heavy menstrual bleeding based on PBAC score over 185 (mean of two control
             cycles)and desire contraception

        Exclusion Criteria:

          -  Menorrhagia of endocrine or systemic origin

          -  other pathology e.g. patients with fibroids of any size, adenomyosis, endometriosis,
             pelvic inflammatory disease.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hatem Abu Hashim, MD MRCOG</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mansoura University Hospitals</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Waleed El-Sherbini, MD</last_name>
    <role>Study Director</role>
    <affiliation>Mansoura University Hospitals</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mohamed Bazeed, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Mansoura University Hospitals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mansoura University Hospitals,OB/GYN department</name>
      <address>
        <city>Mansoura</city>
        <state>Dakahlia Governorate</state>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <reference>
    <citation>Matteson KA, Boardman LA, Munro MG, Clark MA. Abnormal uterine bleeding: a review of patient-based outcome measures. Fertil Steril. 2009 Jul;92(1):205-16. doi: 10.1016/j.fertnstert.2008.04.023. Epub 2008 Jul 16. Review.</citation>
    <PMID>18635169</PMID>
  </reference>
  <reference>
    <citation>Oddsson K, Leifels-Fischer B, Wiel-Masson D, de Melo NR, Benedetto C, Verhoeven CH, Dieben TO. Superior cycle control with a contraceptive vaginal ring compared with an oral contraceptive containing 30 microg ethinylestradiol and 150 microg levonorgestrel: a randomized trial. Hum Reprod. 2005 Feb;20(2):557-62. Epub 2004 Nov 11.</citation>
    <PMID>15539438</PMID>
  </reference>
  <verification_date>December 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 22, 2010</study_first_submitted>
  <study_first_submitted_qc>December 23, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 24, 2010</study_first_posted>
  <last_update_submitted>December 23, 2010</last_update_submitted>
  <last_update_submitted_qc>December 23, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 24, 2010</last_update_posted>
  <responsible_party>
    <name_title>Dr. Hatem Abu Hashim, Associate Prof. of OB/GYN</name_title>
    <organization>Mansoura Faculty of Medicine, Mansoura University.</organization>
  </responsible_party>
  <keyword>Menorrhagia</keyword>
  <keyword>Vaginal ring</keyword>
  <keyword>Norethisterone Acetate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Menorrhagia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Contraceptive Agents</mesh_term>
    <mesh_term>Norethindrone</mesh_term>
    <mesh_term>Norethindrone acetate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

